Cirrhotic Cardiomyopathy
10
6
6
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 10 trials
100.0%
+13.4% vs benchmark
20%
2 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (10)
Prospective Investigation of Cirrhotic Cardiomyopathy in Humans
DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis
Heart Problems in Children With Chronic Liver Disease
Echocardiography-guided Cirrhosis and Liver Failure-Intensive Care Protocol Sepsis
Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival
Ivabradine in Cirrhotic Cardiomyopathy
Cirrhotic Cardiomyopathy Based on Point-of-care Echocardiography, Biomarkers and Histology
Prevalence, Clinical Features and Risk Factors of Cirrhotic Cardiomyopathy Assessed by Two-dimensional Speckle Tracking Imaging
Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis
DOCICAR: Cardiac Dysfunction in Cirrhosis